Active Ingredient History
Simtuzumab is a humanized monoclonal antibody designed for the treatment of fibrosis. It binds to LOXL2 and acts as an immunomodulator. In January 2016, Gilead Sciences terminated its Phase 2 clinical study in patients with idiopathic pulmonary fibrosis (IPF) due to lack of efficacy. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Cholangitis (Phase 2)
Colorectal Neoplasms (Phase 2)
Hepatitis C (Phase 2)
HIV (Phase 2)
HIV Infections (Phase 2)
Idiopathic Pulmonary Fibrosis (Phase 2)
Liver Cirrhosis (Phase 2)
Neoplasms (Phase 1)
Non-alcoholic Fatty Liver Disease (Phase 2)
Pancreatic Neoplasms (Phase 2)
Primary Myelofibrosis (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue